Large drug firms narrow their therapeutic interests

Large drug firms narrow their therapeutic interests

Mergers--and the associated job cuts and pipeline pruning decisions--tend to have devastating effects on research and development productivity. GAVI Alliance CEO Seth Berkley points to experimental respiratory syncytial virus vaccines, meningococcal vaccines, and group B streptococcus vaccines as th...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2014-05, Vol.383 (9932), p.1873-1873
Main Author: Mullard, Asher
Format: Article
Language:eng
Subjects:
Acquisitions & mergers
Biomedical Research - organization & administration
Biomedical Research - trends
Drug Discovery - organization & administration
Drug Discovery - trends
Drug Industry - organization & administration
Drug Industry - trends
Efficiency, Organizational
Humans
Internal Medicine
Pharmaceutical industry
R&D
Research & development
Vaccines
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mergers--and the associated job cuts and pipeline pruning decisions--tend to have devastating effects on research and development productivity. GAVI Alliance CEO Seth Berkley points to experimental respiratory syncytial virus vaccines, meningococcal vaccines, and group B streptococcus vaccines as the most important assets from the global health perspective.
ISSN:0140-6736
1474-547X